Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.2.0.727
Consolidated Balance Sheets - USD ($)
May. 31, 2015
Nov. 30, 2014
Current Assets    
Cash and cash equivalents $ 3,914,021 $ 3,279,267
Restricted cash 204,252 204,141
Marketable securities 532,369 102,674
Accounts receivable (net of allowance for doubtful accounts of $2,151,200 and $1,976,966, respectively) 3,707,192 4,071,997
Prepaid expenses 822,083 710,754
Other current assets 126,864 123,126
Total current assets 9,306,781 8,491,959
Property and Equipment-net 881,260 953,415
Other Assets    
Investment in Saneron CCEL Therapeutics, Inc. 684,000 684,000
Deposits and other assets, net 68,038 80,212
Total other assets 752,038 764,212
Total assets 10,940,079 10,209,586
Current Liabilities    
Accounts payable 1,255,567 992,910
Accrued expenses 1,277,925 1,471,699
Deferred revenue 6,577,368 6,662,552
Total current liabilities 9,110,860 9,127,161
Other Liabilities    
Deferred revenue, net of current portion 10,224,446 9,509,088
Long-term liability - revenue sharing agreements 2,300,000 2,300,000
Total other liabilities $ 12,524,446 $ 11,809,088
Commitments and contingencies (Note 6)    
Stockholders' Deficit    
Preferred stock    
Common stock ($.01 par value, 20,000,000 authorized; 12,225,340 issued and 9,666,203 outstanding as of May 31, 2015 and 11,921,285 issued and 9,706,174 outstanding as of November 30, 2014) $ 122,254 $ 119,213
Additional paid-in capital 28,100,486 27,842,106
Treasury stock, at cost (6,065,111) (5,112,648)
Accumulated other comprehensive income 226,276  
Accumulated deficit (33,079,132) (33,575,334)
Total stockholders' deficit (10,695,227) (10,726,663)
Total liabilities and stockholders' deficit $ 10,940,079 $ 10,209,586
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock